When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Neuropatia diabética

Last reviewed: 21 Jul 2025
Last updated: 08 Apr 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • assintomático
  • dor (periférica)
  • perda da sensação (periférica)
  • disestesia (periférica)
  • reflexos aquileus reduzidos ou ausentes (periféricos)
  • lesões indolores (periféricas)
  • taquicardia de repouso (autonômica)
  • variabilidade da frequência cardíaca prejudicada (autonômica)
  • polaciúria, urgência, noctúria, incontinência, hesitação, fluxo fraco ou retenção (autonômico)
  • disfunção erétil (autonômica)
  • diminuição do desejo sexual e aumento da dor durante a relação (autonômica)
  • hipotensão ortostática (autonômica)
Full details

Other diagnostic factors

  • constipação (autonômica)
  • incontinência fecal (autonômica)
  • anidrose, intolerância ao calor, pele seca ou hiperidrose (autonômica)
  • hipoglicemia assintomática (autonômica)
  • fraqueza (periférica)
  • história de quedas recentes (periférica)
  • ataxia de marcha (periférica)
  • náuseas, vômitos pós-prandiais, distensão abdominal, perda de apetite, saciedade precoce (autonômico)
  • pirose e disfagia para sólidos (autonômica)
  • diarreia profusa e aquosa (autonômica)
  • mononeuropatia específica (periférica)
  • neuropatia craniana (periférica)
  • dor sobre a parede abdominal ou torácica inferior (periférica)
  • atrofia dos músculos da coxa, dor e fraqueza (periférica)
Full details

Risk factors

  • hiperglicemia mal controlada
  • duração prolongada do diabetes
  • idade avançada (por exemplo, >70 anos)
  • alta estatura
  • hipertensão
  • dislipidemia com triglicerídeos elevados
  • coexistência de vários fatores de risco para doença cardiovascular (diabetes do tipo 2)
  • doença renal
  • obesidade
  • desregulação imune
  • tabagismo
  • genética
Full details

Diagnostic investigations

1st investigations to order

  • diagnóstico clínico
  • glicemia de jejum
  • HbA1c
  • hormônio estimulante da tireoide sérico
  • vitamina B12 sérica
  • testes de função renal
  • perfil lipídico sérico
  • TFHs
  • hemograma completo e velocidade de hemossedimentação
  • imunoeletroforese de proteínas séricas/urinárias
Full details

Investigations to consider

  • glicose plasmática de 2 horas
  • estudos de condução nervosa (velocidade de condução nervosa, [VCN])
  • eletromiografia (EMG)
  • teste sensorial quantitativo (TSQ)
  • biópsia de pele
  • estudos dos reflexos cardiovasculares
  • microscopia confocal da córnea
  • variabilidade da frequência cardíaca (VFC)
  • estudos de esvaziamento gástrico
  • gastroduodenoscopia
  • refeição de bário
  • manometria gastrointestinal
  • testes de hidrogênio no ar expirado
  • ultrassonografia gástrica
  • ressonância nuclear magnética (RNM) gástrica
  • manometria anorretal
  • gordura fecal
  • teste de absorção da D-xilose
  • urocultura
  • cistometria, cistometrograma miccional
  • ultrassonografia do trato urinário pós-miccional
  • vídeo-urodinâmica
  • testosterona (matinal)
Full details

Treatment algorithm

ONGOING

neuropatia periférica diabética

neuropatias cranianas

mononeuropatias dos membros ou tronculares

amiotrofia diabética

neuropatia autonômica diabética

Contributors

Authors

Rayaz A. Malik, BSc (Hons), MSc, MBChB, FRCP, PhD

Professor of Medicine

Organizational Official for the Human Research Protection Program

Weill Cornell Medicine - Qatar

Doha

Qatar

Disclosures

RAM has been reimbursed for being on the advisory board for an epidemiological study on cardiovascular disease in type 2 diabetes and to give educational lectures on treatment of diabetes undertaken by Novo Nordisk. RAM has been reimbursed for educational lectures for Sanofi Aventis, Lilly, and Proctor and Gamble (P&G). RAM has received an investigator-initiated grant to study long COVID from P&G. RAM is an author of a number of references cited in this topic.

Uazman Alam, BSc, MBChB, MPHe, PhD

Reader and Consultant Physician

University of Liverpool

Liverpool

UK

Disclosures

UA has received honoraria from Procter & Gamble, Viatris, Grunenthal, Eli Lilly, and Sanofi for educational meetings. UA has also received investigator-led funding from Procter & Gamble.

Shazli Azmi, MBchB, MRCP

Consultant Physician

Diabetes and Endocrinology

Central Manchester Foundation Trust

University of Manchester

Manchester

UK

Disclosures

SA has received honoraria for educational meetings from AstraZeneca, Sanofi, Menarini, Eli Lilly, and Procter & Gamble.

Acknowledgements

Dr Rayaz Malik, Dr Uazman Alam, and Dr Shazli Azmi would like to gratefully acknowledge Dr Rodica Pop-Busui and Dr Eva Feldman, the previous contributors to this topic.

Disclosures

RPB declares that she has received speaking honoraria from Pfizer and research support from Amylin Pharmaceuticals; National Institutes of Health/National Heart, Lung, and Blood Institute; National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases; American Diabetes Association; and Juvenile Diabetes Research Foundation. RPB and EF are authors of references cited in this topic.

Peer reviewers

Zachary T. Bloomgarden, MD

Clinical Professor

Department of Medicine

Mount Sinai School of Medicine

New York

NY

Disclosures

ZTB declares that he has no competing interests.

Rajesh K. Garg, MD

Assistant Professor of Medicine

Harvard Medical School

Division of Endocrinology

Diabetes and Hypertension

Brigham and Women's Hospital

Boston

MA

Disclosures

RKG has received consultant fees from Aventis and Novartis, and speaker fees from Novartis.

Edward Jude, MBBS, MD, MRCP, DNB

Consultant and Honorary Senior Lecturer

Tameside General Hospital

Diabetes Centre

Ashton Under Lyne

Lancashire

UK

Disclosures

EJ has received funding for conferences and lectures from Pfizer and Boehringer Ingelheim.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-54.Full text  Abstract

Dyck PJ, Albers JW, Andersen H, et al; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011 Oct;27(7):620-8.Full text  Abstract

American Diabetes Association Professional Practice Committee. Introduction and methodology: standards of care in diabetes-2025. Diabetes Care. 2025 Jan 1;48(1 suppl 1):S1-5.Full text  Abstract

Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Report of the AAN Guideline Subcommittee. Neurology. 2022 Jan 4;98(1):31-43.Full text  Abstract

Senneville E, Albalawi Z, van Asten SA, et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections. Clin Infect Dis. 2023 Oct 2:ciad527.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Neuropatia diabética images
  • Differentials

    • Uremia
    • Deficiência de cianocobalamina
    • Hipotireoidismo
    More Differentials
  • Guidelines

    • Standards of care in diabetes - 2025
    • Management of type 2 diabetes: a handbook for general practice
    More Guidelines
  • Patient information

    Diabetes: o que posso fazer para me manter saudável?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer